Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01215344 · BASELINE

Baseline characteristics

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade · Source last updated 2018-05-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      33
    2. group Id
      BG001
      value
      3
    3. group Id
      BG002
      value
      36
    units
    Participants
groups
  1. description
    VELCADE, Lenalidomide, Dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle Lenalidomide: 25 mg by mouth on days 1-4 of each cycle Dexamethasone: 20 mg the day before and the day after receiving VELCADE DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Bisphosphonates: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
    id
    BG000
    title
    VRD (VELCADE, Lenalidomide, Dexamethasone)
  2. description
    VELCADE, liposomal doxorubicin, dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Liposomal doxorubicin: 30 mg/m2 on day 4 of each cycle Dexamethasone: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
    id
    BG001
    title
    VDD (VELCADE, Liposomal Doxorubicin, Dexamethasone)
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        title
        <=18 years
      2. measurements
        1. group Id
          BG000
          value
          24
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          27
        title
        Between 18 and 65 years
      3. measurements
        1. group Id
          BG000
          value
          9
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          9
        title
        >=65 years
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Age, Categorical
    unit Of Measure
    Participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          8.71411
          value
          60
        2. group Id
          BG001
          spread
          4.642796
          value
          48
        3. group Id
          BG002
          spread
          8.803890
          value
          58.5
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          13
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          13
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          20
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          23
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          33
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          36
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      33
    2. group Id
      BG001
      value
      3
    3. group Id
      BG002
      value
      36
    units
    Participants
groups
  1. description
    VELCADE, Lenalidomide, Dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle Lenalidomide: 25 mg by mouth on days 1-4 of each cycle Dexamethasone: 20 mg the day before and the day after receiving VELCADE DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Bisphosphonates: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
    id
    BG000
    title
    VRD (VELCADE, Lenalidomide, Dexamethasone)
  2. description
    VELCADE, liposomal doxorubicin, dexamethasone VELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle DVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice Liposomal doxorubicin: 30 mg/m2 on day 4 of each cycle Dexamethasone: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
    id
    BG001
    title
    VDD (VELCADE, Liposomal Doxorubicin, Dexamethasone)
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        title
        <=18 years
      2. measurements
        1. group Id
          BG000
          value
          24
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          27
        title
        Between 18 and 65 years
      3. measurements
        1. group Id
          BG000
          value
          9
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          9
        title
        >=65 years
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Age, Categorical
    unit Of Measure
    Participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          8.71411
          value
          60
        2. group Id
          BG001
          spread
          4.642796
          value
          48
        3. group Id
          BG002
          spread
          8.803890
          value
          58.5
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          13
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          13
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          20
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          23
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          33
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          36
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice